Osteoinductive Factor and Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients: A Literature Review

A. Ramadan
{"title":"Osteoinductive Factor and Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients: A Literature Review","authors":"A. Ramadan","doi":"10.21608/smj.2022.131430.1315","DOIUrl":null,"url":null,"abstract":": Diabetic kidney disease comprises a multifaceted etiopathology that includes glomerular hemodynamic changes, inflammation, oxidative stress, interstitial fibrosis, and tubular atrophy. Diabetic nephropathy (DN), or the pathological alterations in the capillaries caused by diabetes mellitus (DM), is the major cause of end-stage renal disease in diabetic individuals worldwide. Proteinuria, among other elements, as a diagnostic biomarker for DN, is a late change, and so does not detect controlled early nephropathic alterations. This needs the development of novel biomarkers that are more sensitive, specific, and early than proteinuria. Endothelial dysfunction and atherosclerosis are caused by DM, whereas glomerular hypertrophy, an increase in the extracellular matrix, and glomerular sclerosis are caused by DN. Osteogly-cin/Osteoinductive Factor (OGN) is a secretory small leucine-rich matrix/basement proteoglycan that regulates lipid and glucose metabolic activity, collagen fibrillogenesis, and cytokine availability in a paracrine/endocrine manner, and has been linked to the development of atherosclerosis, neovascularization, and angiogenesis. OGN is a pathogenic effector and biomarker that is extremely relevant to DM and DN because of these properties. OGN appears to be a better biomarker for DN than microalbuminuria, according to research. This literature review is intended to offer the most recent findings relevant to OGN's DN biomarker potential.","PeriodicalId":254383,"journal":{"name":"Sohag Medical Journal","volume":"23 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sohag Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/smj.2022.131430.1315","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

: Diabetic kidney disease comprises a multifaceted etiopathology that includes glomerular hemodynamic changes, inflammation, oxidative stress, interstitial fibrosis, and tubular atrophy. Diabetic nephropathy (DN), or the pathological alterations in the capillaries caused by diabetes mellitus (DM), is the major cause of end-stage renal disease in diabetic individuals worldwide. Proteinuria, among other elements, as a diagnostic biomarker for DN, is a late change, and so does not detect controlled early nephropathic alterations. This needs the development of novel biomarkers that are more sensitive, specific, and early than proteinuria. Endothelial dysfunction and atherosclerosis are caused by DM, whereas glomerular hypertrophy, an increase in the extracellular matrix, and glomerular sclerosis are caused by DN. Osteogly-cin/Osteoinductive Factor (OGN) is a secretory small leucine-rich matrix/basement proteoglycan that regulates lipid and glucose metabolic activity, collagen fibrillogenesis, and cytokine availability in a paracrine/endocrine manner, and has been linked to the development of atherosclerosis, neovascularization, and angiogenesis. OGN is a pathogenic effector and biomarker that is extremely relevant to DM and DN because of these properties. OGN appears to be a better biomarker for DN than microalbuminuria, according to research. This literature review is intended to offer the most recent findings relevant to OGN's DN biomarker potential.
2型糖尿病患者骨诱导因子与糖尿病肾病:文献综述
糖尿病肾病包括多方面的病因,包括肾小球血流动力学改变、炎症、氧化应激、间质纤维化和肾小管萎缩。糖尿病肾病(DN)或由糖尿病(DM)引起的毛细血管病理改变是全世界糖尿病患者终末期肾脏疾病的主要原因。蛋白尿,除其他因素外,作为DN的诊断性生物标志物,是一种晚期变化,因此不能检测出受控制的早期肾病改变。这就需要开发比蛋白尿更敏感、更特异、更早的新型生物标志物。内皮功能障碍和动脉粥样硬化是由糖尿病引起的,而肾小球肥大、细胞外基质增加和肾小球硬化是由糖尿病引起的。骨素/骨诱导因子(OGN)是一种分泌小的富含亮氨酸的基质/基底蛋白多糖,以旁分泌/内分泌的方式调节脂质和葡萄糖代谢活性、胶原纤维形成和细胞因子的可用性,并与动脉粥样硬化、新生血管和血管生成的发展有关。OGN是一种致病效应物和生物标志物,由于这些特性与DM和DN极其相关。根据研究,OGN似乎是比微量白蛋白尿更好的DN生物标志物。本文献综述旨在提供与OGN的DN生物标志物潜力相关的最新发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信